Literature DB >> 11719440

T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin.

C D Wolfgang1, M Essand, B Lee, I Pastan.   

Abstract

Previously, we showed that prostate and prostate cancer cells express a truncated T-cell receptor gamma chain mRNA that uses an alternative reading frame to produce a novel nuclear T-cell receptor gamma chain alternate reading frame protein (TARP). TARP is expressed in the androgen-sensitive LNCaP prostate cancer cell line but not in the androgen-independent PC3 prostate cancer cell line, indicating that TARP may play a role in prostate cancer progression. To elucidate the function of TARP, we generated a stable PC3 cell line that expresses TARP in a constitutive manner. Expression of TARP in PC3 cells resulted in a more rapid growth rate with a 5-h decrease in doubling time. cDNA microarray analysis of 6538 genes revealed that caveolin 1, caveolin 2, amphiregulin, and melanoma growth stimulatory activity alpha were significantly up-regulated, whereas IL-1beta was significantly down-regulated in PC3 cells expressing TARP. We also demonstrated that TARP expression is up-regulated by testosterone in LNCaP cells that express a functional androgen receptor. These results suggest that TARP has a role in regulating growth and gene expression in prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719440

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

Review 1.  Strategies to use immune modulators in therapeutic vaccines against cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; Lauren V Wood
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

2.  PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach.

Authors:  Tapan K Bera; Rangan Maitra; Carlo Iavarone; Giuliana Salvatore; Vasantha Kumar; James J Vincent; B K Sathyanarayana; Paul Duray; B K Lee; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

Review 3.  Immunotherapy in prostate cancer: emerging strategies against a formidable foe.

Authors:  Marijo Bilusic; Christopher Heery; Ravi A Madan
Journal:  Vaccine       Date:  2011-07-07       Impact factor: 3.641

4.  Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.

Authors:  Sandra M Lopez; Alexander I Agoulnik; Manqi Zhang; Leif E Peterson; Egla Suarez; Gregory A Gandarillas; Anna Frolov; Rile Li; Kimal Rajapakshe; Christian Coarfa; Michael M Ittmann; Nancy L Weigel; Irina U Agoulnik
Journal:  Clin Cancer Res       Date:  2016-03-11       Impact factor: 12.531

5.  TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.

Authors:  Lauren V Wood; Antonio Fojo; Brenda D Roberson; Meghan S B Hughes; William Dahut; James L Gulley; Ravi A Madan; Philip M Arlen; Marianna Sabatino; David F Stroncek; Luciano Castiello; Jane B Trepel; Min-Jung Lee; Howard L Parnes; Seth M Steinberg; Masaki Terabe; Julia Wilkerson; Ira Pastan; Jay A Berzofsky
Journal:  Oncoimmunology       Date:  2016-07-01       Impact factor: 8.110

6.  Identification of candidate prostate cancer genes through comparative expression-profiling of seminal vesicle.

Authors:  Maxwell Thompson; Jacques Lapointe; Yoon-La Choi; David E Ong; John P Higgins; James D Brooks; Jonathan R Pollack
Journal:  Prostate       Date:  2008-08-01       Impact factor: 4.104

Review 7.  Oncolytic virotherapy for urological cancers.

Authors:  Zahid Delwar; Kaixin Zhang; Paul S Rennie; William Jia
Journal:  Nat Rev Urol       Date:  2016-05-24       Impact factor: 14.432

8.  Molecular characterization of the feline T-cell receptor γ alternate reading frame protein (TARP) ortholog.

Authors:  Alexander Th A Weiss; Marie-Charlotte von Deetzen; Werner Hecht; Manfred Reinacher; Achim D Gruber
Journal:  J Vet Sci       Date:  2012-12       Impact factor: 1.672

9.  Trial watch: Peptide vaccines in cancer therapy.

Authors:  Erika Vacchelli; Isabelle Martins; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

10.  Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.

Authors:  Malka Epel; Irit Carmi; Sharon Soueid-Baumgarten; SangKon Oh; Tapan Bera; Ira Pastan; Jay Berzofsky; Yoram Reiter
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 6.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.